Molecular mechanisms linking geranylgeranyl diphosphate synthase to cell survival and proliferation

References

• Adnane J, Bizouarn FA, Qian Y, Hamilton AD, Sebti SM. 1998. P21wafi/cipi is upregulated by the geranylgeranyltransferase i inhibitor ggti-298 through a transforming growth factor b- and sp1-responsive element: involvement of the small gtpase rhoa. Mol Cell Biol 18:6962–6970.
   PubMed Web of Science ®Google Scholar
• Alan JK, Lundquist EA. 2013. Mutationally activated rho gtpases in cancer. Small GTPases 4:159–163.
   PubMedGoogle Scholar
• Allal C, Favre G, Couderc B, Salicio S, Sixou S, Hamilton AD, et al. 2000. Rhoa prenylation is required for promotion of cell growth and transformation and cytoskeleton organization but not for induction of serum response element transcription. J Biol Chem 275:31001–31008.
   PubMed Web of Science ®Google Scholar
• Allal C, Pradines A, Hamilton AD, Sebti SM, Favre G. 2002. Farnesylated rhob prevents cell cycle arrest and actin cytoskeleton disruption caused by the geranylgeranyltransferase i inhibitor ggti-298. Cell Cycle 1:430–437.
   PubMed Web of Science ®Google Scholar
• Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE, Perrone MH. 1992. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33:1657–1663.
   PubMed Web of Science ®Google Scholar
• Baba TT, Nemoto TK, Miyazaki T, Oida S. 2008. Simvastatin suppresses the differentiation of c2c12 myoblast cells via a rac pathway. J Muscle Res Cell Motil 29:127–134.
   PubMed Web of Science ®Google Scholar
• Barney RJ, Wasko BM, Dudakovic A, Hohl RJ, Wiemer DF. 2010. Synthesis and biological evaluation of a series of aromatic bisphosphonates. Bioorg Med Chem 18:7212–7220.
   PubMed Web of Science ®Google Scholar
• Baulch-Brown C, Molloy TJ, Yeh SL, Ma D, Spencer A. 2007. Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma. Leuk Res 31:341–352.
   PubMed Web of Science ®Google Scholar
• Benford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ. 1999. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 56:131–140.
   PubMed Web of Science ®Google Scholar
• Bennis F, Favre G, Le Gaillard F, Soula G. 1993. Importance of mevalonate-derived products in the control of hmg-coa reductase activity and growth of human lung adenocarcinoma cell line a549. Int J Cancer 55:640–645.
   PubMed Web of Science ®Google Scholar
• Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G. 2000. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 373:231–241.
   PubMed Web of Science ®Google Scholar
• Berndt N, Hamilton AD, Sebti SM. 2011. Targeting protein prenylation for cancer therapy. Nat Rev Cancer 11:775–791.
   PubMed Web of Science ®Google Scholar
• Blanco-Colio LM, Villa A, Ortego M, Hernandez-Presa MA, Pascual A, Plaza JJ, Egido J. 2002. 3-hydroxy-3-methyl-glutaryl coenzyme a reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of bcl-2 expression and rho a prenylation. Atherosclerosis 161:17–26.
   PubMed Web of Science ®Google Scholar
• Brinkkoetter PT, Gottmann U, Schulte J, Van Der Woude FJ, Braun C, Yard BA. 2006. Atorvastatin interferes with activation of human cd4(+) t cells via inhibition of small guanosine triphosphatase (gtpase) activity and caspase-independent apoptosis. Clin Exp Immunol 146:524–532.
   PubMed Web of Science ®Google Scholar
• Brown MS, Goldstein JL. 1980. Multivalent feedback regulation of hmg coa reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 21:505–517.
   PubMed Web of Science ®Google Scholar
• Brown MS, Goldstein JL. 1997. The srebp pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89:331–340.
   PubMed Web of Science ®Google Scholar
• Brown MS, Goldstein JL. 2009. Cholesterol feedback: from schoenheimer’s bottle to scap’s meladl. J Lipid Res 50(Suppl.):S15–S27.
   PubMed Web of Science ®Google Scholar
• Chen CK-M, Hudock MP, Zhang Y, Guo RT, Cao R, No JH, et al. 2008. Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J Med Chem 51:5594–5607.
   PubMed Web of Science ®Google Scholar
• Chen SH, Lin SW, Lin SR, Liang PH, Yang JM. 2013. Moiety-linkage map reveals selective nonbisphosphonate inhibitors of human geranylgeranyl diphosphate synthase. J Chem Inf Model 53:2299–2311.
   PubMed Web of Science ®Google Scholar
• Ciosek CP Jr, Magnin DR, Harrity TW, Logan JV, Dickson JK Jr, Gordon EM, et al. 1993. Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo. J Biol Chem 268:24832–24837.
   PubMed Web of Science ®Google Scholar
• Clendening JW, Pandyra A, Boutros PC, El Ghamrasni S, Khosravi F, Trentin GA, et al. 2010. Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci USA 107:15051–15056.
   PubMed Web of Science ®Google Scholar
• Clezardin P, Benzaid I, Croucher PI. 2011. Bisphosphonates in preclinical bone oncology. Bone 49:66–70.
   PubMed Web of Science ®Google Scholar
• Cox AD, Der CJ, Philips MR. 2015. Targeting ras membrane association: back to the future for anti-ras drug discovery? Clin Cancer Res 21:1819–1827.
   PubMed Web of Science ®Google Scholar
• Dai Y, Khanna P, Chen S, Pei XY, Dent P, Grant S. 2007. Statins synergistically potentiate 7-hydroxystaurosporine (ucn-01) lethality in human leukemia and myeloma cells by disrupting ras farnesylation and activation. Blood 109:4415–4423.
   PubMed Web of Science ®Google Scholar
• Denoyelle C, Hong L, Vannier JP, Soria J, Soria C. 2003. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual rhoa-dependent and -independent effects. Br J Cancer 88:1631–1640.
   PubMed Web of Science ®Google Scholar
• Dunford JE, Rogers MJ, Ebetino FH, Phipps RJ, Coxon FP. 2006. Inhibition of protein prenylation by bisphosphonates causes sustained activation of rac, cdc42, and rho gtpases. J Bone Miner Res 21:684–694.
   PubMed Web of Science ®Google Scholar
• Dykstra KM, Allen C, Born EJ, Tong H, Holstein SA. 2015. Mechanisms for autophagy modulation by isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells. Oncotarget 6:41535–41549.
   PubMed Web of Science ®Google Scholar
• Ebetino FH, Hogan AM, Sun S, Tsoumpra MK, Duan X, Triffitt JT, et al. 2011. The relationship between the chemistry and biological activity of the bisphosphonates. Bone 49:20–33.
   PubMed Web of Science ®Google Scholar
• Falsetti SC, Wang DA, Peng H, Carrico D, Cox AD, Der CJ, et al. 2007. Geranylgeranyltransferase i inhibitors target ralb to inhibit anchorage-dependent growth and induce apoptosis and rala to inhibit anchorage-independent growth. Mol Cell Biol 27:8003–8014.
   PubMed Web of Science ®Google Scholar
• Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R, et al. 2012. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148:244–258.
   PubMed Web of Science ®Google Scholar
• Fromigue O, Hay E, Modrowski D, Bouvet S, Jacquel A, Auberger P, Marie PJ. 2006. Rhoa gtpase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-mapks-bcl-2 signaling independently of bmp-2 and cell differentiation. Cell Death Differ 13:1845–1856.
   PubMed Web of Science ®Google Scholar
• Ghosh PM, Ghosh-Choudhury N, Moyer ML, Mott GE, Thomas CA, Foster BA, et al. 1999. Role of rhoa activation in the growth and morphology of a murine prostate tumor cell line. Oncogene 18:4120–4130.
   PubMed Web of Science ®Google Scholar
• Gnant M. 2012. Adjuvant bisphosphonates: a new standard of care? Curr Opin Oncol 24:635–642.
   PubMed Web of Science ®Google Scholar
• Gokey NG, Lopez-Anido C, Gillian-Daniel AL, Svaren J. 2011. Early growth response 1 (egr1) regulates cholesterol biosynthetic gene expression. J Biol Chem 286:29501–29510.
   PubMed Web of Science ®Google Scholar
• Guo RT, Cao R, Liang PH, Ko TP, Chang TH, Hudock MP, et al. 2007. Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc Natl Acad Sci USA 104:10022–10027.
   PubMed Web of Science ®Google Scholar
• Hendrix A, Maynard D, Pauwels P, Braems G, Denys H, Van Den Broecke R, et al. 2010. Effect of the secretory small gtpase rab27b on breast cancer growth, invasion, and metastasis. J Natl Cancer Inst 102:866–880.
   PubMedGoogle Scholar
• Hirai A, Nakamura S, Noguchi Y, Yasuda T, Kitagawa M, Tatsuno I, et al. 1997. Geranylgeranylated rho small gtpase(s) are essential for the degradation of p27kip1 and facilitate the progression from g1 to s phase in growth-stimulated rat frtl-5 cells. J Biol Chem 272:13–16.
   PubMed Web of Science ®Google Scholar
• Hottman DA, Li L. 2014. Protein prenylation and synaptic plasticity: implications for Alzheimer’s disease. Mol Neurobiol 50:177–185.
   PubMed Web of Science ®Google Scholar
• Hua X, Yokoyama C, Wu J, Briggs MR, Brown MS, Goldstein JL, Wang X. 1993. Srebp-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element. Proc Natl Acad Sci USA 90:11603–11607.
   PubMed Web of Science ®Google Scholar
• Ibrahim A, Scher N, Williams G, Sridhara R, Li N, Chen G, et al. 2003. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res 9:2394–2399.
   PubMed Web of Science ®Google Scholar
• Inoue R, Matsuki NA, Jing G, Kanematsu T, Abe K, Hirata M. 2005. The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the pi3k-akt-nfkappab pathway in osteosarcoma cells. Br J Pharmacol 146:633–641.
   PubMed Web of Science ®Google Scholar
• Jiang P, Mukthavaram R, Chao Y, Nomura N, Bharati IS, Fogal V, et al. 2014. In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells. Br J Cancer 111:1562–1571.
   PubMed Web of Science ®Google Scholar
• Kavanagh KL, Dunford JE, Bunkoczi G, Russell RG, Oppermann U. 2006. The crystal structure of human geranylgeranyl pyrophosphate synthase reveals a novel hexameric arrangement and inhibitory product binding. J Biol Chem 281:22004–22012.
   PubMed Web of Science ®Google Scholar
• Kuzuguchi T, Morita Y, Sagami I, Sagami H, Ogura K. 1999. Human geranylgeranyl diphosphate synthase. Cdna cloning and expression. J Biol Chem 274:5888–5894.
   PubMed Web of Science ®Google Scholar
• Li X, Liu L, Tupper JC, Bannerman DD, Winn RK, Sebti SM, et al. 2002. Inhibition of protein geranylgeranylation and rhoa/rhoa kinase pathway induces apoptosis in human endothelial cells. J Biol Chem 277:15309–15316.
   PubMed Web of Science ®Google Scholar
• Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, et al. 2001. Evaluation of farnesyl:Protein transferase and geranylgeranyl:Protein transferase inhibitor combinations in preclinical models. Cancer Res 61:8758–8768.
   PubMed Web of Science ®Google Scholar
• Maeda A, Yano T, Itoh Y, Kakumori M, Kubota T, Egashira N, Oishi R. 2010. Down-regulation of rhoa is involved in the cytotoxic action of lipophilic statins in hepg2 cells. Atherosclerosis 208:112–118.
   PubMed Web of Science ®Google Scholar
• Maurer-Stroh S, Koranda M, Benetka W, Schneider G, Sirota FL, Eisenhaber F. 2007. Towards complete sets of farnesylated and geranylgeranylated proteins. PLoS Comput Biol 3:e66.
   PubMed Web of Science ®Google Scholar
• McCormick F. 2015. The potential of targeting ras proteins in lung cancer. Expert Opin Ther Targets 19:451–454.
   PubMed Web of Science ®Google Scholar
• Miyagi Y, Matsumura Y, Sagami H. 2007. Human geranylgeranyl diphosphate synthase is an octamer in solution. J Biochem 142:377–381.
   PubMed Web of Science ®Google Scholar
• Mo H, Elson CE. 2004. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med (Maywood) 229:567–585.
   PubMed Web of Science ®Google Scholar
• Nagata Y, Kontani K, Enami T, Kataoka K, Ishii R, Totoki Y, et al. 2016. Variegated rhoa mutations in adult t-cell leukemia/lymphoma. Blood 127:596–604.
   PubMed Web of Science ®Google Scholar
• Okamoto S, Jiang Y, Kawamura K, Shingyoji M, Tada Y, Sekine I, et al. 2014. Zoledronic acid induces apoptosis and s-phase arrest in mesothelioma through inhibiting rab family proteins and topoisomerase ii actions. Cell Death Dis 5:e1517.
   PubMed Web of Science ®Google Scholar
• Padavano J, Henkhaus RS, Chen H, Skovan BA, Cui H, Ignatenko NA. 2015. Mutant k-ras promotes invasion and metastasis in pancreatic cancer through gtpase signaling pathways. Cancer Growth Metastasis 8:95–113.
   PubMedGoogle Scholar
• Palsuledesai CC, Distefano MD. 2015. Protein prenylation: enzymes, therapeutics, and biotechnology applications. ACS Chem Biol 10:51–62.
   PubMed Web of Science ®Google Scholar
• Pandyra AA, Mullen PJ, Goard CA, Ericson E, Sharma P, Kalkat M, et al. 2015. Genome-wide rnai analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell death. Oncotarget 6:26909–26921.
   PubMed Web of Science ®Google Scholar
• Poulter CD, Argyle JC, Mash EA. 1978. Farnesyl pyrophosphate synthetase. Mechanistic studies of the 1'-4 coupling reaction with 2-fluorogeranyl pyrophosphate. J Biol Chem 253:7227–7233.
   PubMed Web of Science ®Google Scholar
• Preudhomme C, Roumier C, Hildebrand MP, Dallery-Prudhomme E, Lantoine D, Lai JL, et al. 2000. Nonrandom 4p13 rearrangements of the rhoh/ttf gene, encoding a gtp-binding protein, in non-hodgkin's lymphoma and multiple myeloma. Oncogene 19:2023–2032.
   PubMed Web of Science ®Google Scholar
• Qiu RG, Chen J, Mccormick F, Symons M. 1995. A role for rho in ras transformation. Proc Natl Acad Sci USA 92:11781–11785.
   PubMed Web of Science ®Google Scholar
• Reid TS, Terry KL, Casey PJ, Beese LS. 2004. Crystallographic analysis of caax prenyltransferases complexed with substrates defines rules of protein substrate selectivity. J Mol Biol 343:417–433.
   PubMed Web of Science ®Google Scholar
• Reilly JE, Neighbors JD, Tong H, Henry MD, Hohl RJ. 2015. Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis. Clin Exp Metastasis 32:555–566.
   PubMed Web of Science ®Google Scholar
• Russell RGG, Watts NB, Ebetino FH, Rogers MJ. 2008. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporosis Int 19:733–759.
   PubMed Web of Science ®Google Scholar
• Shen N, Shao Y, Lai SS, Qiao L, Yang RL, Xue B, et al. 2011. Ggpps, a new egr-1 target gene, reactivates erk 1/2 signaling through increasing ras prenylation. Am J Pathol 179:2740–2750.
   PubMed Web of Science ®Google Scholar
• Shipman CM, Croucher PI, Russell RG, Helfrich MH, Rogers MJ. 1998. The bisphosphonate incadronate (ym 175) causes apoptosis of human myeloma cels in vitro by inhibiting the mevalonate pathway. Cancer Res 58:5294–5297.
   PubMed Web of Science ®Google Scholar
• Shull LW, Wiemer AJ, Hohl RJ, Wiemer DF. 2006. Synthesis and biological activity of isoprenoid bisphosphonates. Bioorg Med Chem 14:4130–4136.
   PubMed Web of Science ®Google Scholar
• Sonnemann J, Bumbul B, Beck JF. 2007. Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro. Mol Cancer Ther 6:2976–2984.
   PubMed Web of Science ®Google Scholar
• Stigter EA, Guo Z, Bon RS, Wu YW, Choidas A, Wolf A, et al. 2012. Development of selective, potent rabggtase inhibitors. J Med Chem 55:8330–8340.
   PubMed Web of Science ®Google Scholar
• Szabo CM, Matsumura Y, Fukura S, Martin MB, Sanders JM, Sengupta S, et al. 2002. Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents. J Med Chem 45:2185–2196.
   PubMed Web of Science ®Google Scholar
• Tang D, Park HJ, Georgescu SP, Sebti SM, Hamilton AD, Galper JB. 2006. Simvastatin potentiates tumor necrosis factor alpha-mediated apoptosis of human vascular endothelial cells via the inhibition of the geranylgeranylation of rhoa. Life Sci 79:1484–1492.
   PubMed Web of Science ®Google Scholar
• Tanida I, Ueno T, Kominami E. 2008. Lc3 and autophagy. Methods Mol Biol 445:77–88.
   PubMedGoogle Scholar
• Tao W, Shi JF, Zhang Q, Xue B, Sun YJ, Li CJ. 2013. Egr-1 enhances drug resistance of breast cancer by modulating mdr1 expression in a ggpps-independent manner. Biomed Pharmacother 67:197–202.
   PubMed Web of Science ®Google Scholar
• Terpos E, Berenson J, Raje N, Roodman GD. 2014. Management of bone disease in multiple myeloma. Expert Rev Hematol 7:113–125.
   PubMed Web of Science ®Google Scholar
• Tsubaki M, Itoh T, Satou T, Imano M, Komai M, Ogawa N, et al. 2013. Nitrogen-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of ras signaling pathways and bim-mediated activation of the intrinsic apoptotic pathway. Biochem Pharmacol 85:163–172.
   PubMed Web of Science ®Google Scholar
• Van Beek E, Lowik C, Van Der Pluijm G, Papapoulos S. 1999a. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 14:722–729.
   PubMed Web of Science ®Google Scholar
• Van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S. 1999b. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 264:108–111.
   PubMed Web of Science ®Google Scholar
• Van De Donk NW, Kamphuis MM, Van Kessel B, Lokhorst HM, Bloem AC. 2003. Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing mcl-1 protein levels. Blood 102:3354–3362.
   PubMed Web of Science ®Google Scholar
• Wasko BM, Dudakovic A, Hohl RJ. 2011. Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate. J Pharmacol Exp Ther 337:540–546.
   PubMed Web of Science ®Google Scholar
• Wennerberg K, Rossman KL, Der CJ. 2005. The ras superfamily at a glance. J Cell Sci 118:843–846.
   PubMed Web of Science ®Google Scholar
• Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, et al. 1997. K- and n-ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272:14459–14464.
   PubMed Web of Science ®Google Scholar
• Wiemer AJ, Hohl RJ, Wiemer DF. 2009. The intermediate enzymes of isoprenoid metabolism as anticancer targets. Anticancer Agents Med Chem 9:526–542.
   PubMed Web of Science ®Google Scholar
• Wiemer AJ, Tong H, Swanson KM, Hohl RJ. 2007. Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase. Biochem Biophys Res Commun 353:921–925.
   PubMed Web of Science ®Google Scholar
• Wiemer AJ, Wiemer DF, Hohl RJ. 2011. Geranylgeranyl diphosphate synthase: an emerging therapeutic target. Clin Pharmacol Ther 90:804–812.
   PubMed Web of Science ®Google Scholar
• Wiemer AJ, Yu JS, Lamb KM, Hohl RJ, Wiemer DF. 2008. Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors. Bioorg Med Chem 16:390–399.
   PubMed Web of Science ®Google Scholar
• Wills VS, Allen C, Holstein SA, Wiemer DF. 2015. Potent triazole bisphosphonate inhibitor of geranylgeranyl diphosphate synthase. ACS Med Chem Lett 6:1195–1198.
   PubMed Web of Science ®Google Scholar
• Xia Y, Liu YL, Xie Y, Zhu W, Guerra F, Shen S, et al. 2014. A combination therapy for kras-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin. Sci Transl Med 6:263ra161.
   PubMed Web of Science ®Google Scholar
• Yanae M, Tsubaki M, Satou T, Itoh T, Imano M, Yamazoe Y, Nishida S. 2011. Statin-induced apoptosis via the suppression of erk1/2 and akt activation by inhibition of the geranylgeranyl-pyrophosphate biosynthesis in glioblastoma. J Exp Clin Cancer Res 30:74.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Clark MF, Stern PH. 2009. The small gtpase rhoa is crucial for mc3t3-e1 osteoblastic cell survival. J Cell Biochem 106:896–902.
   PubMed Web of Science ®Google Scholar
• Yu DC, Liu J, Chen J, Shao JJ, Shen X, Xia HG, et al. 2014. Ggpps1 predicts the biological character of hepatocellular carcinoma in patients with cirrhosis. BMC Cancer 14:248.
   PubMed Web of Science ®Google Scholar
• Yu X, Shen N, Zhang ML, Pan FY, Wang C, Jia WP, et al. 2011. Egr-1 decreases adipocyte insulin sensitivity by tilting pi3k/akt and mapk signal balance in mice. EMBO J 30:3754–3765.
   PubMed Web of Science ®Google Scholar
• Zafar S, Coates DE, Cullinan MP, Drummond BK, Milne T, Seymour GJ. 2014. Zoledronic acid and geranylgeraniol regulate cellular behaviour and angiogenic gene expression in human gingival fibroblasts. J Oral Pathol Med 43:711–721.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cao R, Yin F, Hudock MP, Guo RT, Krysiak K, et al. 2009. Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an x-ray and nmr investigation. J Am Chem Soc 131:5153–5162.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhu W, Liu YL, Wang H, Wang K, Li K, et al. 2013. Chemo-immunotherapeutic anti-malarials targeting isoprenoid biosynthesis. ACS Med Chem Lett 4:423–427.
   PubMed Web of Science ®Google Scholar
• Zhou X, Ferree SD, Wills VS, Born EJ, Tong H, Wiemer DF, Holstein SA. 2014. Geranyl and neryl triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase. Bioorg Med Chem 22:2791–2798.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Casey PJ, Kumar AP, Pervaiz S. 2013. Deciphering the signaling networks underlying simvastatin-induced apoptosis in human cancer cells: evidence for non-canonical activation of rhoa and rac1 gtpases. Cell Death Dis 4:e568.
   PubMed Web of Science ®Google Scholar